S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
Log in

OptimizeRx Stock Price, Forecast & Analysis (NASDAQ:OPRX)

$9.74
+0.01 (+0.10 %)
(As of 11/18/2019 11:22 AM ET)
Today's Range
$9.69
Now: $9.74
$9.74
50-Day Range
$9.65
MA: $12.80
$15.16
52-Week Range
$8.92
Now: $9.74
$17.24
Volume200 shs
Average Volume145,386 shs
Market Capitalization$138.02 million
P/E Ratio194.80
Dividend YieldN/A
Beta0.42
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6568

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.21 million
Cash Flow$0.07 per share
Book Value$2.90 per share

Profitability

Net Income$230,000.00

Miscellaneous

Employees37
Market Cap$138.02 million
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.


OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.15. The business had revenue of $5 million for the quarter, compared to the consensus estimate of $7.21 million. OptimizeRx had a negative return on equity of 3.68% and a negative net margin of 5.32%. View OptimizeRx's Earnings History.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for OptimizeRx.

What price target have analysts set for OPRX?

2 equities research analysts have issued 12 month target prices for OptimizeRx's shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate OptimizeRx's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 115.6% from the stock's current price. View Analyst Price Targets for OptimizeRx.

What is the consensus analysts' recommendation for OptimizeRx?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptimizeRx.

Has OptimizeRx been receiving favorable news coverage?

News stories about OPRX stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OptimizeRx earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for OptimizeRx.

Are investors shorting OptimizeRx?

OptimizeRx saw a increase in short interest in October. As of October 15th, there was short interest totalling 770,700 shares, an increase of 7.4% from the September 15th total of 717,900 shares. Based on an average trading volume of 97,100 shares, the days-to-cover ratio is currently 7.9 days. Approximately 6.5% of the company's shares are sold short. View OptimizeRx's Current Options Chain.

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Stag Industrial (STAG), NVIDIA (NVDA), Amgen (AMGN), Inpixon (INPX), Amarin (AMRN), Conatus Pharmaceuticals (CNAT), Exelixis (EXEL) and Harvard Bioscience (HBIO).

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the folowing people:
  • Mr. William J. Febbo, CEO & Director (Age 50)
  • Ms. Miriam J. Paramore, Pres (Age 56)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
  • Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
  • Mr. James Brooks, Consultant (Age 50)

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Calamos Advisors LLC (2.21%), 1492 Capital Management LLC (1.66%), Russell Investments Group Ltd. (1.41%), Perkins Capital Management Inc. (1.31%), Cadence Capital Management LLC (1.12%) and Rice Hall James & Associates LLC (0.60%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Institutional Ownership Trends for OptimizeRx.

Which major investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., 1492 Capital Management LLC and Perkins Capital Management Inc.. View Insider Buying and Selling for OptimizeRx.

Which major investors are buying OptimizeRx stock?

OPRX stock was acquired by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Rice Hall James & Associates LLC, Calamos Advisors LLC and P.A.W. Capital Corp. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Insider Buying and Selling for OptimizeRx.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $9.74.

How big of a company is OptimizeRx?

OptimizeRx has a market capitalization of $138.02 million and generates $21.21 million in revenue each year. The company earns $230,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. OptimizeRx employs 37 workers across the globe.View Additional Information About OptimizeRx.

What is OptimizeRx's official website?

The official website for OptimizeRx is http://www.optimizerx.com/.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected]


MarketBeat Community Rating for OptimizeRx (NASDAQ OPRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about OptimizeRx and other stocks. Vote "Outperform" if you believe OPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel